August 3, 2026Clinical Cancer ResearchNCT04251416 (investigator-initiated, single-center)
Sacituzumab Govitecan Shows 28% Response Rate in Recurrent Endometrial Cancer
A single-center, investigator-initiated Phase II trial using a Simon two-stage design tested sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, in 50 evaluable patients with recurrent or persistent endometrial cancer who had progressed after platinum-based chemotherapy, enrolled between March 2020 and December 2024.